Prostate cancer cells depend on signaling through the androgen receptor (AR) to grow and survive. Many anti-cancer therapies that target ARs are initially successful in patients, including a class of drugs known as CYP17A1 inhibitors, which interfere with AR signaling by blocking the synthesis of androgen. However, over time, adaptations to AR expression and function… Continue reading An Additional Strategy for Targeting Treatment-Resistant Prostate Cancer